Please login to the form below

Not currently logged in
Email:
Password:

NICE backs two cancer drugs

Boehringer’s Giotrif and Janssen’s Velcade given final go-ahead for NHS use
National Institute for Health and Care Excellence NICE logo

The National Institute for Health and Care Excellence (NICE) has given definitive backing to two cancer drugs for routine use on the NHS in England and Wales.

Cost-effectiveness body NICE issued final guidance recommending Boehringer Ingelheim's Giotrif (afatinib) for use in the treatment of lung cancer, while Janssen's Velcade (bortezomib) was given the green light to treat blood cancer multiple myeloma.

With its recommendation, Giotrif becomes the third drug recommended by NICe that is a personalised treatment for people with non-small-cell lung cancer (NSCLC).

It follows positive guidance for personalised lung cancer medicines Roche's Tarceva (erlotinib) and AstraZeneca's Iressa (gefitinib), both of which are also targeted at patients who have the EGFR-TK genetic mutation.

The specific recommend for Giotrif covers patients who have non-small-cell lung cancer which is locally advanced or has spread to other parts of the body.

The NICE recommendation is another positive step forward for Boehringer's relatively new oncology ambitions, which bore its first fruit with the approval of Giotrif last year.

Elsewhere, NICE backed Janssen's Velcade as a first treatment for people with multiple myeloma before bone marrow transplant.

“The evidence presented to our independent committee showed that having bortezomib at this stage will help more patients go on to a bone marrow transplant, and consequently prevent the disease from progressing for longer,” said Professor Carole Longson, director of the NICE centre for health technology evaluation.

The decision comes after a troubled review period for Velcade, which was initially turned down in this indication in 2013.

Article by
Thomas Meek

23rd April 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Chandler Chicco Companies US

Chandler Chicco Companies (CCC) is a global health communications group that delivers unmatched perspective and creative know-how. Today, healthcare is...

Latest intelligence

Free White Paper: Customer Experience for Pharma
To learn why an effective customer experience strategy is vital for pharma, download our white paper “Customer experience for pharma” to learn more....
How ethical is your brand plan? Introducing the hEQ.
Assess your brand plan’s Healthcare Ethics Quotient and see how these questions can give your brand plan a new perspective and engage your internal teams and external customers....
solution_options.png
Why e-detailing must give options to healthcare professionals
We know, we know. You want to talk about your treatment right away, but this really is an essential step that will make your e-detailing even more credible....